During this cooking tutorial, this woman tries to show how to cook chestnuts. She forgets that overheated chestnuts are vulnerable to explosion, and the chestnut winds up exploding. BBC leaders resign ...

Judge says Greenpeace must pay $345 million in pipeline lawsuit, cutting jury amount nearly in half Republican senators strongly rebuke Trump's NATO troop withdrawal Dodgers make lineup changes for ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...

Those with prostate cancer that returns after surgery or radiation—and typically face a high risk of the disease spreading and death—could benefit from a new drug combination. A Cedars-Sinai Medical ...

One of the shape primitives you'll use most often in your OpenSCAD designs is the cube. Rounding the edges of cube-like objects impacts both the visual appeal and functional aspects of the final ...

Teemo lives up to his name as one of the most toxic characters in the Riot Games IP. This little creature is one of the latest characters released into 2XKO, and many are wondering what the best Teemo ...

From how to French brain or play the guitar to how to unclog a sing or perform CPR, you can learn all kinds of useful skills on YouTube. We at Mental Floss are always eager to learn new things and ...

Texas A&M will be looking to continue its undefeated season in Week 8 when the Aggies travel to Fayetteville to take on the Arkansas Razorbacks. These two teams have played their games at AT&T Stadium ...

Late-breaking results from the PROMPT-AF, CRRF-PeAF, TRIM-AF and ARREST-AF trials presented at AHA 2024 shed new light on cutting-edge approaches to revolutionizing the management of patients with ...

NASHVILLE, Tenn. (WZTV) — A groundbreaking study at Vanderbilt University Medical Center (VUMC) is changing the face of kidney cancer treatment. Doctors say a once-experimental drug combination is now ...

Enfortumab vedotin and pembrolizumab combination achieved a 39% objective response rate in PD-L1 positive recurrent/metastatic HNSCC patients. Disease control rate was 75.6%, with responses observed ...